Maryanne Covington
Research Subjects
Maryanne Covington has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Stacey Shepard
Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, DE 19803, USA
6 shared publications - Yanlong Li
Incyte Research Institute, Incyte Corporation, 1801 Augustine Road, Wilmington, DE 19803, USA
6 shared publications - Andrew P Combs5 shared publications
- Andrew W Buesking5 shared publications
- Artem Shvartsbart5 shared publications
- Brent Douty
Incyte Corporation, Discovery Chemistry, Experimental Station, Route 141 and Henry Clay Road, Wilmington, DE 19880, USA
5 shared publications
Latest Publications
- Open Access
- 8 July 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (7) , 1044
Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Named after the two-faced Roman god of doorways, Janus kinases (JAKs) represent a class of tyrosine kinases. The JAK signaling pathway is pivotal for the downstream signaling of inflammatory cytokines, including interleukins, interferons, and multiple growth factors. This article provides an overview of the JAK pathway and signaling, its significance in immune-mediated dermatologic diseases and the development of a targeted, localized option of a selective JAK inhibitor, ruxolitinib cream. In the early 1990s, various discovery and clinical development programs were initiated to explore pharmaceutical inhibition of the JAK-STAT pathway. Incyte Corporation launched a strategy to identify molecules suitable for both topical as well as oral delivery. Ruxolitinib was designed as a molecule with low nanomolar potency selective for JAK1 and 2 enzymes, but without significant inhibition of non-JAK kinases, as well as physicochemical properties for both topical and oral administration. An oil-in-water emulsified ruxolitinib cream formulation was developed for topical application and was studied in multiple immune-mediated dermatologic diseases including psoriasis, alopecia areata, atopic dermatitis and vitiligo. Ruxolitinib cream represents a novel, JAK1/2 selective therapy that can be delivered directly to the skin to treat a number of cytokine-driven, inflammatory dermatoses.
- 8 July 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (7) , 1044
Open AccessDeveloping a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
Named after the two-faced Roman god of doorways, Janus kinases (JAKs) represent a class of tyrosine kinases. The JAK signaling pathway is pivotal for the downstream signaling of inflammatory cytokines, including interleukins, interferons, and multiple growth factors. This article provides an overview of the JAK pathway and signaling, its significance in immune-mediated dermatologic diseases and the development of a targeted, localized option of a selective JAK inhibitor, ruxolitinib cream. In the early 1990s, various discovery and clinical development programs were initiated to explore pharmaceutical inhibition of the JAK-STAT pathway. Incyte Corporation launched a strategy to identify molecules suitable for both topical as well as oral delivery. Ruxolitinib was designed as a molecule with low nanomolar potency selective for JAK1 and 2 enzymes, but without significant inhibition of non-JAK kinases, as well as physicochemical properties for both topical and oral administration. An oil-in-water emulsified ruxolitinib cream formulation was developed for topical application and was studied in multiple immune-mediated dermatologic diseases including psoriasis, alopecia areata, atopic dermatitis and vitiligo. Ruxolitinib cream represents a novel, JAK1/2 selective therapy that can be delivered directly to the skin to treat a number of cytokine-driven, inflammatory dermatoses.
- Open Access
- 1 September 2020
- Published by Elsevier in Clinical Immunology
- Vol. 218, 108517
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
- 1 September 2020
- Published by Elsevier in Clinical Immunology
- Vol. 218, 108517
Open AccessInhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment